The targeted therapy onalespib has shown effectiveness in preclinical studies of glioblastoma by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital ...
A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative ...
Tyrosine kinase inhibitors, such as crizotinib and erlotinib, are widely used to treat non-small-cell lung cancer, but after initial response, relapse is common because of the emergence of resistance ...
The targeted therapy onalespib has shown effectiveness in preclinical studies of glioblastoma by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital ...
Pan-tumor prognostic value of multiple immune protein expressions. Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating ...
This study showed that the targeted drug onalespib reduced the expression of cell-survival proteins such as AKT and endothelial growth factor receptor in glioma cell lines and glioma stem cells from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results